• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Novartis Venture Funds

edit

Novartis Ventures focuses primarily on the development of novel therapeutics and platforms. They balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In their investments, they look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program.

They prefer to have their initial investment at the early stage to build the company and follow with additional investment in pace with the company’s progress. They continue their approach of larger focused investments and anticipate total investments up to USD 15 – 20 mil per company over its life, but it can be as little as 100,000 USD to get started. They will increase their activities to lead or co-lead deals further and remain open to participate in larger syndicates.

Sectors

• New therapeutics & platforms
• Medical devices/implants
• Diagnostics/biomarkers
• Drug delivery/biopolymers

Recent Milestones

edit

• 
  Novartis Venture Funds invested in Aileron Therapeutic. (1/14/13)
  Posted 1/14/13 at 7:06pm via finsmes.com
• 
  Novartis Venture Funds invested in Thesan Pharmaceuticals. (10/31/12)
  Posted 10/31/12 at 8:52pm via finsmes.com
• 
  Novartis Venture Funds invested in ImaginAb. (3/27/12)
  Posted 3/27/12 at 5:23pm via finsmes.com
• 
  Novartis Venture Funds invested in BioRelix. (3/22/12)
  Posted 3/22/12 at 6:19pm via masshightech.com
• 
  Novartis Venture Funds invested in Celladon. (2/15/12)
  Posted 2/15/12 at 6:31pm via finsmes.com
• 
  Novartis Venture Funds invested in Advanced Animal Diagnostics. (3/15/11)
  Posted 3/15/11 at 11:00pm via advancedanimaldiagnostics.com
• 
  Novartis Venture Funds invested in Euthymics Bioscience. (3/9/11)
  Posted 3/9/11 at 8:25pm via masshightech.com
• 
  Novartis Venture Funds invested in Covagen. (11/29/10)
  Posted 11/29/10 at 7:26pm via covagen.com
• 
  Novartis Venture Funds invested in Foldrx Pharmaceuticals. (6/15/10)
  Posted 6/16/10 at 6:01am via fiercebiotech.com
• 
  Novartis Venture Funds invested in Immune Targeting Systems. (3/17/10)
  Posted 3/18/10 at 3:32am via onbiovc.com
• 
  Novartis Venture Funds invested in Evolva. (12/11/09)
  Posted 12/16/09 at 1:16am via dowjones.com
• 
  Novartis Venture Funds invested in Intellikine. (7/22/09)
  Posted 7/28/09 at 1:25pm via onbiovc.com
• 
  Novartis Venture Funds invested in Aileron Therapeutic. (6/11/09)
  Posted 6/15/09 at 10:24pm via zibb.com
• 
  Novartis Venture Funds invested in Alios BioPharma. (6/11/09)
  Posted 6/12/09 at 8:28am via fiercebiotech.com
• 
  Novartis Venture Funds invested in Alios BioPharma. (2/12/09)
  Posted 4/17/09 at 4:11am via aliosbiopharma.com
• 
  Novartis Venture Funds invested in Diagnoplex. (12/13/08)
  Posted 6/16/09 at 12:40am via bio-medicine.org

Investments

Videos

Sources

1. Aileron Therapeutics Raises $12M in Series D Financing (finsmes.com) [edit]
2. Thesan Pharmaceuticals Closes $16M Series A Financing (finsmes.com) [edit]
3. ImaginAb Completes $12.5M Series A Financing (finsmes.com) [edit]
4. Connecticut biotech raises $2.56M round (masshightech.com) [edit]
5. Celladon Closes $43M in Funding (finsmes.com) [edit]
6. Advanced Animal Diagnostics Raises $11 Million in Equity Financing (advancedanimaldiagnostics.com) [edit]
7. Euthymics Bioscience bumps Series A to $28M (masshightech.com) [edit]
8. Covagen closes Series A financing round with Seroba Kernel as lead investor (covagen.com) [edit]
9. FoldRx banks $29M for neurodegenerative drug application (fiercebiotech.com) [edit]
10. Immune Targeting Systems, Ltd.: Series A $13.2 (onbiovc.com) [edit]
11. Evolva Goes Public In Reverse Merger, Raises $43M (fis.dowjones.com) [edit]
12. Intellikine, Inc.: Series B $51M (onbiovc.com) [edit]
13. Aileron Therapeutics Closes Series D Financing (zibb.com) [edit]
14. Alios raises another $8M (fiercebiotech.com) [edit]
15. Alios BioPharma, Inc. Completes First Closing of Series A Financing with Commitment of $24 MM from 3 (aliosbiopharma.com) [edit]
16. Diagnoplex Closes CHF10 Million ($8.3 Million) Series A Financing (bio-medicine.org) [edit]
17. Catalyst Biosciences Raises $40 Million in Series C Financing (fiercebiotech.com) [edit]
18. Proteostasis Therapeutics Secures a $45 Million Series A Financing to Develop Proteostasis Regulator(TM) Drugs (reuters.com) [edit]
19. Capital Funding Report [edit]
20. Aileron ramps up business on heels of positive results (boston.bizjournals.com) [edit]
21. Capital Funding Report [edit]
22. Cellerix closes €27,2m financing round to bring product Cx401 to market (cellerix.com) [edit]
23. Neovacs, a leading biotech company in the field of therapeutic vaccines in oncology and inflammatory diseases, raises 13 million Euros from a international group of specialist investors, including the Novartis Venture Fund and Truffle Capital (neovacs.fr) [edit]
24. Nutmeg State biotech lands $25.8M in round one (masshightech.com) [edit]
25. Aileron scores $7M in new venture funds (fiercebiotech.com) [edit]
26. INTRADIGM ANNOUNCES SIGNIFICANT ENHANCEMENTS OF THE COMPANY CAPABILITIES, A NEW SERIES A FINANCING AND IMPORTANT ADDITION TO SENIOR MANAGEMENT TEAM (intradigm.com) [edit]
27. EraGen (eragen.com) [edit]